1 Epidemiological feature, viral shedding, and antibody seroconversion
2 among asymptomatic SARS-CoV-2 carriers and symptomatic/
3 presymptomatic COVID-19 patients

4 Yi Chen ^{a,1}, Ping Li ^{b,1}, Yi-Bo Ding ^{b,1}, Miao Liu ^{c,1}, Lei-Jie Liu ^{c,1}, Bo Yi ^a, Ting Wu ^b,
5 Hong-Jun Dong ^a, Xu-Ying Lao ^a, Ke-Qing Ding ^a, Hai-Bo Wang ^a, Dong-Liang
6 Zhang ^a, Xiao-Jie Tan ^b, Zhong-Fa Wang ^c, Guo-Zhang Xu ^{a,*}, Guang-Wen Cao ^{b,*}

7 ^a Ningbo Municipal center for disease control and prevention, Ningbo, Zhejiang
8 315010, China.

9 ^b Department of Epidemiology, Second Military Medical University, Shanghai 200433,
10 China.

11 ^c Center of Disease Control and Prevention of Putuo district, Zhoushan 316100, China

12 ¹These authors contributed equally to this work.

13 **Authors for correspondence:** Professor Guang-wen Cao, Department of
14 Epidemiology, Second Military Medical University, Shanghai, 200433, China. Email
15 address: gcao@smmu.edu.cn, tel: 86-21-81871060; Director Guo-zhang Xu, Ningbo
16 Municipal center for disease control and prevention, Ningbo, Zhejiang 315010, China.
17 Email address: xugz@nbcddc.org.cn , tel: 86-574-87274539.

18

19

Summary

Novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pandemic. However, data concerning the epidemiological features, viral shedding, and antibody dynamics between asymptomatic SARS-CoV-2 carriers and COVID-19 patients remain controversial. We enrolled 193 subjects infected with SARS-CoV-2 in Ningbo and Zhoushan, Zhejiang, China from January 21 to March 6, 2020. All subjects were followed up to monitor the dynamics of immunoglobulin M (IgM) and IgG against SARS-CoV-2. Of those, 31 were asymptomatic carriers, 149 were symptomatic patients, and 14 were presymptomatic patients. Compared to symptomatic patients, asymptomatic carriers were younger and had higher levels of white blood cell and lymphocyte, lower levels of C-reactive protein and viral load, and shorter viral shedding duration. Conversion of IgM from positive to negative was shorter in asymptomatic carriers than in COVID-19 patients ($P=0.030$). The proportion of those persistently seropositive for IgG was higher in COVID-19 patients than in asymptomatic carriers ($P=0.037$). Viral load was higher in symptomatic than presymptomatic patients. Viral shedding was longer in presymptomatic patients than in asymptomatic carriers. Conclusively, asymptomatic carriers have a higher antiviral immunity to clear SARS-CoV-2 than do symptomatic patients and this antiviral immunity is not contributable to humoral immunity.

42 **Keywords:** Asymptomatic carriers; Intra-familial transmission; SARS-CoV-2;
43 COVID-19

44

45 INTRODUCTION

46

47 Novel coronavirus disease in 2019 (COVID-19) caused by severe acute respiratory
48 syndrome coronavirus 2 (SARS-CoV-2) has being pandemic since it was firstly
49 recognized in China in late December 2019 [1]. The case number keeps increasing.
50 Globally, as of 9:42am CET, December 11, 2020, there have been 68,845,368
51 confirmed cases of COVID-19, including 1,570,304 deaths, reported to World Health
52 Organization [2]. Family clustering and hospital-based transmission were the two
53 major epidemiological features of this outbreak at the early stage, and continued to be
54 an important cause of community-based SARS-CoV-2 transmission in a low
55 prevalence region [3-6]. COVID-19 patients and asymptomatic carriers are the main
56 sources of SARS-CoV-2 infection but might have differences in some features [7].
57 However, data concerning SARS-CoV-2 transmission and viral shedding duration
58 between COVID-19 patients and asymptomatic SARS-CoV-2 carriers remain
59 controversial. It has been summarized from early studies that viral load of
60 asymptomatic carriers is comparable to symptomatic patients [8]. In another study, it
61 has been demonstrated that a considerably higher viral load is present in samples from
62 fatal cases compared to asymptomatic carriers [9]. Difference in the dynamics of
63 antibody against SARS-CoV-2 between asymptomatic carriers and COVID-19

64 patients remains unknown. To provide the information for recognizing differences
65 between asymptomatic and symptomatic SARS-CoV-2 infected subjects, we
66 conducted a study to investigate the epidemiological feature, laboratory findings, viral
67 shedding, and antibody conversion of SARS-CoV-2 infected cases among
68 asymptomatic SARS-CoV-2 carriers and symptomatic/presymptomatic COVID
69 patients in two cities, a low prevalence region in Zhejiang, China.

70

71 **METHODS**

72

73 **Study design and patients**

74

75 It is an ambispective cohort study. The study enrolled all confirmed cases with
76 SARS-CoV-2 infection on Ningbo city and a familial clustering infection with
77 SARS-Co-2 in Putuo district of Zhoushan city from January 21 to March 6, 2020.
78 Epidemiological, clinical characteristics, pathogen and serological test results were
79 collected by Ningbo Municipal Center for Disease Control and Prevention (Ningbo
80 CDC) and CDC of Putuo district, Zhoushan (Putuo CDC). Some baseline information
81 including demographic and pathogenic data of those patients were reported [10, 11].
82 After that, we continued to investigate viral load and viral shedding of SARS-CoV-2,
83 laboratory tests, and the dynamics of serum immunoglobulin M (IgM) and
84 immunoglobulin G (IgG) against SARS-CoV-2 between asymptomatic carriers and
85 COVID-19 patients. All patients were followed up to monitor the dynamics of IgM

and IgG against SARS-CoV-2. Those with antibody tests for two times or more within 160 days were included in antibody seroconversion analysis. Diagnoses and disease staging of COVID-19 were carried out according to the Protocol for the Diagnosis and Treatment of COVID-19 (Version 7th), National Health Commission of the People's Republic of China [12]. Specifically, COVID-19 was diagnosed if the patient was tested positive for SARS-CoV-2 genomic RNA and accompanied by clinical symptoms including fever and cough. Asymptomatic carrier was identified in close contactors of COVID-19 patients if they did not have any symptom. We also classified as COVID-19 patients with onset of disease and those during the incubation period (presymptomatic). All diagnosed COVID-19 patients were classified as mild, common, severe, and extremely severe types. This study was approved by the Ethics Commissions of Ningbo CDC and Putuo CDC. Written informed consent was waived for emerging infectious diseases.

Epidemiological survey

A semi-structured questionnaire was applied to obtain demographic information, exposure information of the familiar clustering cases via face-to-face interview and telephone calls by well-trained professionals. The data regarding any travel history to high risk areas with COVID-19 epidemic, contact with confirmed cases or asymptomatic carriers tested positive for SARS-CoV-2 genomic RNA, contact with patients with some symptoms like fever, dry cough, and expectoration in the past 2-3

108 weeks before illness onset. Any chance and duration of attending any kinds of
109 population gatherings were recorded as well.

110

111 Clinical information included the date of symptom onset and admission to designated
112 hospitals, clinical manifestation, routine laboratory examinations, and radiographic
113 examinations. The clinical manifestations, chest computed tomography images, and
114 laboratory results of patients in Ningbo were collected from the electronic medical
115 record systems in the two designated hospitals: Ningbo First Hospital and Huamei
116 Hospital. The information of patients from Zhoushan was collected from Zhoushan
117 Maternal and Child Health Care Hospital and Putuo Hospital. Two researchers (PL
118 and YD) independently reviewed all of the data to doubly check the accuracy of data
119 collected.

120

121 **Examination of SARS-CoV-2 genomic RNA**

122

123 Quantitative reverse transcription-PCR (qRT-PCR) assay was applied to detect
124 SARS-CoV-2 genomic RNA in nasal and throat swabs, sputum, and feces of patients.
125 Patients in Ningbo were examined using the test kits manufactured by Shanghai
126 BioGerm Medical Technology (Shanghai, China) and Daan Gene Co., Ltd
127 (Guangzhou, China) [13]. Patients in Zhoushan were examined using the test kits
128 manufactured by Shanghai GeneoDx Biotech Company (Shanghai, China) [14].
129 Sample was positive if the cycling threshold (CT) values of reverse-transcription

130 polymerase chain reaction (RT-PCR) for the ORF1ab and the N genes were less than
131 37. Sample was negative if no CT value, or CT value of greater than 40, or
132 unrepeatable CT value in the range of 37-40.

133

134 **Detection of antibodies against SARS-COV-2**

135

136 IgM and IgG against SARS-CoV-2 in the frozen reserved fasting serum samples were
137 detected using the diagnostic enzyme-linked immunosorbent assay (ELISA) kits. The
138 diagnostic kits used for Ningbo patients and Zhoushan patients were manufactured by
139 Innovita Biological Technology (Tangshan, China) and Nanjing Wending Biotech
140 Company (Nanjing, China), respectively [15]. Briefly, testing results by Innovita
141 ELISA kits were determined by the color reaction. Dark band was considered positive.
142 Light band indicated weak positive. Disappearance of the expected band was
143 considered negative. Testing results by Wending ELISA kits were presented as
144 OD/CO. Sample was positive if the ratio of optical density (OD) to the cut-off value
145 (CO) was equal or greater than 1 and negative if the ratio was less than 1. A higher
146 OD/CO value indicated a higher level of antibody concentration.

147

148 **Statistical Analysis**

149

150 Categorical variables were presented as count (%) and compared using the χ^2 test or
151 the Fisher exact test. Continuous variables were described using median and
152 interquartile range (IQR) values and then compared using Mann-Whitney U test or

153 Kruskal Wallis test. These statistical analyses were two-sided and performed using R,
154 version 3.6.2 (R Foundation for Statistical Computing, Canberra, Austria). Scatter
155 diagram to demonstrate the distribution of IgM and IgG against SARS-CoV-2 among
156 asymptomatic carriers and symptomatic and presymptomatic COVID-19 patients
157 were generated by R software. A *P* value of <0.05 was considered significant for two
158 independent groups. An adjusted *P* value of <0.017 was considered significant by
159 Bonferroni-Dunn test for pairwise comparison among three groups.

160

161 **RESULTS**

162

163 **Epidemiological characteristics of asymptomatic SARS-CoV-2 carriers,** 164 **symptomatic COVID-19 patients, and presymptomatic COVID-19 patients**

165

166 A total of 193 SARS-CoV-2 infected subjects were enrolled in this study. Of those, 31
167 were asymptomatic carriers, 148 were symptomatic COVID-19 patients, and 14 were
168 presymptomatic COVID-19 patients. Of the 187 patients from Ningbo, 3 family
169 clusters were included. Those patients were close contacts of confirmed COVID-19
170 patients and then tested positive for SARS-CoV-2 genomic RNA, from January 21 to
171 March 6, 2020. For a family cluster from Putuo, a 41-year-old man, who once
172 contacted with a COVID-19 relative, was the first case diagnosed as COVID-19. The
173 other five family members were close contacts of the man. All family members were
174 tested positive for SARS-CoV-2 genomic RNA, with 1 asymptomatic SARS-CoV-2
175 carrier and 5 symptomatic COVID-19 cases. Our epidemiological survey indicated
176 the family members did not have opportunity to get the infection from other sources.

177

178 Asymptomatic SARS-CoV-2 carriers were significantly younger than symptomatic
179 COVID-19 patients and presymptomatic COVID-19 patients. Compared to
180 symptomatic COVID-19 patients, asymptomatic SARS-CoV-2 carriers had higher
181 levels of circulating white blood cell (WBC) and lymphocyte, lower levels of
182 C-reactive protein (CRP) and viral load, and shorter viral shedding time. Interestingly,
183 viral load was significantly lower in presymptomatic COVID-19 patients than in
184 symptomatic COVID-19 patients. The viral shedding duration was significantly
185 longer in presymptomatic COVID-19 patients than in asymptomatic carriers. The
186 first-time serological tests showed that nearly one-third of asymptomatic carriers and
187 symptomatic COVID-19 patients were seronegative for IgM against SARS-CoV-2
188 while the seronegative rates for IgG to SARS-CoV-2 were around 7% in the two
189 populations, respectively ([Table 1](#)).

190

191 **Dynamics in seroconversion of IgM and IgG against SARS-CoV-2 between** 192 **asymptomatic carriers and COVID-19 patients**

193

194 Of the 193 study subjects, 74 (15 asymptomatic carriers and 59 COVID-19 patients)
195 had two consecutive test results of IgM and IgG against SARS-CoV-2 within 160
196 days. SARS-CoV-2-specific IgM seroconversion from positive to negative or weak
197 positive occurred in 9 (60.0%) asymptomatic carriers, while this occurred in 28
198 (47.5%) COVID-19 patients ($P=0.647$). However, the median time interval of IgM
199 seroconversion from positive to negative was 7.50 (IQR, 4.75-11.50) days in

asymptomatic carriers, which was significantly shorter than 25.50 (IQR, 6.75-56.75) days in COVID-19 patients ($P=0.030$). SARS-CoV-2-specific IgG seroconversion from positive to negative or weak positive occurred in 8 (53.4%) asymptomatic carriers, while this occurred in 15 (25.5%) COVID-19 patients ($P=0.059$). Importantly, 5 (33.3%) of asymptomatic carriers were consistently seropositive for IgG against SARS-CoV-2, however, this was 39 (66.1%) in COVID-19 patients ($P=0.037$). Furthermore, there was no significant difference in the time interval of IgG seroconversion between the two groups (Table 2, Figure 1).

208

209 **Intrafamilial transmission of SARS-CoV-2**

210

Four family clusters were recorded in the study, 3 from Ningbo and 1 from Zhoushan. A total of 15 subjects (7 asymptomatic carriers and 8 COVID-19 patients) were confirmed to be infected by SARS-CoV-2 in the 4 familial clusters. Of the 7 asymptomatic carriers, 3 were children at the age of 12 years or younger, 3 adults aged from 18 to 60 years, and a 75-year-old woman. Of the 8 COVID-19 cases, 4 were older than 60 years and diagnosed as severe cases, 3 of the 4 severe cases had underlying diseases. The remaining 4 were mild patients at the age between 18 and 60 years. Only one of the 4 mild cases had an underlying disease. Although intra-familial transmission was the major cause of acquiring SARS-CoV-2 infection, the proportion of those who acquired SARS-CoV-2 infection via intra-familial transmission was significantly higher in asymptomatic carriers than in COVID-19 patients (89% vs. 61%, $P=0.028$) (Figure 2). In the familial cluster in Putuo, the index case's wife who acquired the infection from his husband had a typical dynamic feature in antibodies. The titers of IgM and IgG started to decrease after nearly a

month's increase after the exposure, and then increased again (Figure 3). The second increase in IgM and IgG against SARS-CoV-2 was correlated to the time that she took care of her parents who had severe COVID-19 in the hospital.

228

229 Discussion

230

To characterize the epidemiological features including immunological response, viral transmission, and antibody seroconversion in asymptomatic SARS-CoV-2 carriers, we made a comprehensive comparison between asymptomatic carriers and COVID-19 patients in this study. Compared to symptomatic COVID-19 patients, asymptomatic SARS-CoV-2 carriers were younger and had higher levels of circulating WBC and lymphocyte and a lower level of CRP. These data indicate that asymptomatic carriers have a stronger antiviral immunity and a lower level of systemic inflammation. It has been proven that innate and adaptive lymphocytes and inflammatory factors were closely related to disease progression of COVID-19, from mild to severe [16, 17]. In a previous prospective study, we have demonstrated that lower circulating counts of T lymphocytes, CD4⁺ T cells, and CD8⁺ T cells as well as higher circulating levels of neutrophil proportion, neutrophil/lymphocyte ratio, interleukin-6, CRP, and procalcitonin facilitate the progression of COVID-19. Of those, CD8⁺ T cell exhaustion plays an important role in the pathogenesis of COVID-19 [18]. Other studies have also shown that disease severity is negatively associated with NK cells and CD3⁺, CD4⁺, and CD8⁺ T lymphocyte levels, while intensive expansion of highly cytotoxic effector T cell subsets, such as CD4⁺ effector-granulysin, CD8⁺ effector-granulysin, and NKT CD160, is associated with convalescence of COVID-19 patients [19-21]. These evidences strongly indicate that

250 damage of innate immunity and T cell-mediated immunity, which might be caused by
251 proinflammatory factor-induced inflammation, play key roles in the development of
252 COVID-19.

253

254 In this study, we also found that around 7% of asymptomatic carriers and COVID-19
255 patients during or after the incubation were seronegative for IgG against SARS-CoV-2,
256 indicating SARS-CoV-2 infection might not induce sufficient humoral immunity
257 against SARS-CoV-2. In the follow-up study, IgM seroconversion from positive to
258 negative was much faster in asymptomatic carriers than in COVID-19 patients
259 ($P=0.030$). The overall rate of IgG seroconversion from positive to negative or weak
260 positive was around 30% within 160 days after the diagnosis ([Table 2](#)), indicating that
261 IgG against SARS-CoV-2 is not stable. Virus-specific IgG decayed substantially in
262 most individuals [[22](#)]. This was also observed in Importantly, seroconversion of IgG
263 against SARS-CoV-2 from positive to negative or weak positive occurred 53.4% in
264 asymptomatic carriers and 25.5% in COVID-19 patients ($P=0.059$), while
265 consistently seropositive rate of IgG against SARS-CoV-2 was significantly higher in
266 COVID-19 patients than in asymptomatic carriers ($P=0.037$). The similar
267 observations concerning rapid seroconversion of the antibody against SARS-CoV-2 or
268 short-lived immune response after mild infection were also reported in the frontline
269 health care personnel in the US and active workers in France [[23](#), [24](#)]. These data
270 indicate that humoral immunity against SARS-CoV-2 was not efficiently aroused by a
271 relative short exposure of SARS-CoV-2 in asymptomatic carriers or in those with a
272 stronger innate and cell immunity. Long-term seropositive rate of antibody against
273 SARS-CoV-2 in COVID-19 patients, which has been previously reported [[25](#), [26](#)],
274 indicates the feasibility of antibody-generating vaccination in the worldwide

275 prophylactic effort. However, repeat exposure to the same virus may arouse a higher
 276 humoral immunity. A family cluster occurred in Putuo, Zhoushan should be a suitable
 277 example to address this issue ([Figure 3](#)). The index patient's wife should be once
 278 more infected by the same SARS-CoV-2 from her patients, because both antibodies
 279 increased again after declined. Our data imply that boosting vaccination with
 280 SARS-CoV-2 might be important.

281

282 Interestingly, compared to COVID-19 patients, asymptomatic carriers had a lower
 283 level of viral load and shorter viral shedding time ([Table 1](#)). Our finding is different
 284 from a study carried out in Chongqing that asymptomatic carriers had a significantly
 285 longer duration of viral shedding than the symptomatic patients, possibly because
 286 asymptomatic carriers contained presymptomatic patients in the reported study [[27](#)].
 287 In this study, we confirmed that the viral shedding duration was significantly longer in
 288 presymptomatic COVID-19 patients than in asymptomatic carrier ([Table 1](#)). Lower
 289 viral load and shorter viral shedding duration in asymptomatic carriers should be
 290 unlikely caused by the neutralizing antibody, because the antibody, either IgM or IgG,
 291 was declining more rapidly in asymptomatic carriers than in COVID-19 patients.
 292 Innate immunity and cell-mediated immunity should play key roles in repressing viral
 293 replication in asymptomatic carriers [[28](#)]. Lower viral load and shorter viral shedding
 294 time should be due to a relative stronger antiviral immunity, as a high viral load often
 295 predisposes adverse outcomes of COVID-19 [[9](#), [29](#)]. To develop effective vaccine
 296 against SARS-CoV-2, it is important to arouse the specific cell immunity, instead of
 297 focusing on humoral immunity.

298

299 In this study, we found that viral load increased from presymptomatic to symptomatic
300 COVID-19 patients ([Table 1](#)), indicating that infectivity should be the highest at the
301 stage of disease onset. Asymptomatic carriers had a lower level of viral load and
302 shorter viral shedding duration, indicating that the transmissibility of asymptomatic
303 carriers was relative weaker. In the 4 familial clusters, we found that asymptomatic
304 carriers were mostly children and young adults, mild patients were young and
305 middle-aged adults between 18 and 60 years, and severe cases were older than 60
306 years with underlying diseases. Family members were exposed to the same source of
307 infection. However, they had diverse clinical manifestations: children were often
308 asymptomatic whereas old members were very sick. This observation is quite in
309 consistent with the findings of large epidemiological studies that children acquire
310 SARS-CoV-2 infection mostly have mild respiratory symptoms or are asymptomatic,
311 whereas elderly patients with COVID-19, especially male patients, are more likely to
312 progress into severe-type and even die of this disease [[30-33](#)]. Thus, the host
313 immunity and underlying inflammation, which is often affected by ageing, underlying
314 diseases, and dysregulated macrophage response [[35](#)], should be the major
315 determinants of disease severity of COVID-19. Although asymptomatic carriers often
316 acquire the infection from family members, they can transmit SARS-CoV-2 into
317 family members and hospital centers, and eventually kill aged members. As a
318 considerable percentage of SARS-CoV-2 infections may be asymptomatic or
319 presymptomatic, enhanced testing approaches may be needed to detect those who
320 transmit the virus.

321

322 Our study has some limitations. First, follow-up should be extended to observe the
323 duration of SARS-CoV-2-specific antibodies. Second, sample size of asymptomatic
324 carriers with SARS-CoV-2 infected was relatively small.

325

326 **Conclusions**

327

328 Asymptomatic carriers have a higher level of antiviral immunity and lower level of
329 inflammation to clear SARS-CoV-2, resulting in a lower capacity of SARS-CoV-2
330 transmission, than do symptomatic COVID-19 patients. This antiviral immunity
331 should not be contributable to humoral immunity because both IgM and IgG against
332 SARS-CoV-2 are declining more rapidly in asymptomatic carriers than in COVID-19
333 patients. The severity of COVID-19 is associated with older age and underlying
334 diseases in familial clustering cases. Our data also suggest that boosting vaccination
335 with SARS-CoV-2 should be important. This study may help not only in elucidating
336 the mechanisms by which SARS-CoV-2 interacts with host immunity in determining
337 the outcome of SARS-CoV-2 infection, but also in optimizing the strategy for the
338 worldwide prophylactic action to develop SARS-CoV-2 vaccine.

339

340 **Acknowledgments**

341

342 We acknowledge all health-care workers involved in the diagnosis and treatment of
343 patients in Ningbo and Zhoushan. We thank Ningbo CDC and Putuo CDC for
344 providing data for patients with SARS-CoV-2.

345

346 **Ethics approval and consent to participate**

347

348 This study was approved by the Ethics Commission of Ningbo CDC and Putuo CDC.

349

350 **Availability of data and materials**

351

352 The datasets used and analyzed during the current study are available from the
353 corresponding author on reasonable request.

354

355 **Conflicts of Interest**

356 None

357

358 **Funding**

359

360 This study was supported by grants from National Natural Science Foundation of
361 China (82041022), Science and Technology Commission Shanghai Municipality (No.
362 20JC1410200; 20431900404), Science and Technology Bureau of Putuo district,
363 Zhoushan Municipality (No. 2020GY306), and Ningbo Science and Technology
364 Major Project (2020C50001).

365

366 **References**

367 1. Zhu N, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N*

368 *Engl J Med.* 2020;382:727-733. doi: 10.1056/NEJMoa2001017.

369 2. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int>

370 3. Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel

371 coronavirus indicating person-to-person transmission: a study of a family

372 cluster. *Lancet.* 2020;395:514-523. doi:10.1016/S0140-6736(20)30154-9

373 4. Kluytmans-van den Bergh MFQ, Buiting AGM, Pas SD. Prevalence and Clinical

374 Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in

375 2 Dutch Hospitals During an Early Phase of the Pandemic. *JAMA Netw Open.*

376 2020;3(5):e209673. doi:10.1001/jamanetworkopen.2020.9673

377 5. Xia XY, et al. Epidemiological and initial clinical characteristics of patients with

378 family aggregation of COVID-19. *J Clin Virol.* 2020;127:104360.

379 doi:10.1016/j.jcv.2020.104360

380 6. Gonzalez-Reiche AS, et al. Introductions and early spread of SARS-CoV-2 in the

381 New York City area. *Science.* 2020;369:297-301. doi: 10.1126/science.abc1917.

382 7. Ng OT, et al. SARS-CoV-2 seroprevalence and transmission risk factors among

383 high-risk close contacts: a retrospective cohort study. *Lancet Infect Dis.*

384 2020:S1473-3099(20)30833-1. doi: 10.1016/S1473-3099(20)30833-1.

385 8. Huff HV, Singh A. Asymptomatic transmission during the COVID-19 pandemic

386 and implications for public health strategies. *Clin Infect Dis.* 2020:ciaa654. doi:

387 10.1093/cid/ciaa654.

- 388 9. Gorzalski AJ, et al. Characteristics of viral specimens collected from asymptomatic
389 and fatal cases of COVID-19. *J Biomed Res.* 2020;34:431-436. doi:
390 10.7555/JBR.34.20200110.
- 391 10. Chen Y, et al. Epidemiological characteristics of infection in COVID-19 clo
392 se contacts in Ningbo city. *Chin J Epidemiol.* 2020;41:667-671. [In Chinese]. d
393 oi: 10.3760/cma.j.cn112338-20200304-00251.
- 394 11. Li P, et al. Transmission of COVID-19 in the terminal stages of the incubation
395 period: A familial cluster. *Int J Infect Dis.* 2020;96:452-453. doi:
396 10.1016/j.ijid.2020.03.027.
- 397 12. National Health Commission of the People's Republic of China. Diagnosis and
398 Treatment Protocol for COVID-19 (Trial Version 7). (updated: 2020-03-29) Available
399 from: http://en.nhc.gov.cn/2020-03/29/c_78469.htm
- 400 13. Wang M, et al. Analytical performance evaluation of five RT-PCR kits for severe
401 acute respiratory syndrome coronavirus 2. *J Clin Lab Anal.* 2020:e23643. doi:
402 10.1002/jcla.23643.
- 403 14. Shen C, et al. Treatment of 5 Critically Ill Patients With COVID-19 With
404 Convalescent Plasma. *JAMA.* 2020;323:1582-1589. doi: 10.1001/jama.2020.4783.
- 405 15. Teng J, et al. Detection of IgM and IgG antibodies against SARS-CoV-2 in
406 patients with autoimmune diseases. *Lancet Rheumatol.* 2020;2:e384-e385. doi:
407 10.1016/S2665-9913(20)30128-4.
- 408 16. Odak I, et al. Reappearance of effector T cells is associated with recovery from

409 COVID-19. *EBioMedicine*. 2020;57:102885. doi: 10.1016/j.ebiom.2020.102885.

410 17. Sekine T, et al. Robust T Cell Immunity in Convalescent Individuals with
411 Asymptomatic or Mild COVID-19. *Cell*. 2020;183:158-168.e14. doi:
412 10.1016/j.cell.2020.08.017.

413 18. Yang PH, et al. Increased circulating level of interleukin-6 and CD8⁺ T cell
414 exhaustion are associated with progression of COVID-19. *Infect Dis Poverty*.
415 2020;9:161. doi: 10.1186/s40249-020-00780-6.

416 19. Chen J, et al. Clinical characteristics of asymptomatic carriers of novel cor
417 onavirus disease 2019: A multi-center study in Jiangsu Province. *Virulence*. 202
418 0;11:1557-1568. doi: 10.1080/21505594.2020.1840122.

419 20. Li M, et al. Elevated Exhaustion Levels of NK and CD8⁺ T Cells as Indicators for
420 Progression and Prognosis of COVID-19 Disease. *Front Immunol*. 2020;11:580237.
421 doi: 10.3389/fimmu.2020.580237.

422 21. Zhang JY, et al. Single-cell landscape of immunological responses in patients with
423 COVID-19. *Nat Immunol*. 2020;21:1107-1118. doi: 10.1038/s41590-020-0762-x.

424 22. Chen Y, et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody
425 Production. *Cell*. 2020;183:1496-1507.e16. doi: 10.1016/j.cell.2020.10.051.

426 23. Self WH, et al. Decline in SARS-CoV-2 antibodies after mild infection among
427 frontline health care personnel in a multistate hospital network - 12 states,
428 April-August 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69:1762-1766. doi:

429 10.15585/mmwr.mm6947a2.

430 24. Anna F, et al. High seroprevalence but short-lived immune response to
431 SARS-CoV-2 infection in Paris. *Eur J Immunol*. 2020. doi: 10.1002/eji.202049058.

432 25. Long QX, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19.
433 *Nat Med*. 2020;26:845-848. doi: 10.1038/s41591-020-0897-1.

434 26. Ni L, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in
435 COVID-19 Convalescent Individuals. *Immunity*. 2020;52:971-977.e3. doi:
436 10.1016/j.immuni.2020.04.023.

437 27. Long QX, et al. Clinical and immunological assessment of asymptomatic
438 SARS-CoV-2 infections. *Nat Med*. 2020;26:1200-1204. doi:
439 10.1038/s41591-020-0965-6.

440 28. V Vetter P, et al. Daily Viral Kinetics and Innate and Adaptive Immune Re
441 sponse Assessment in COVID-19: a Case Series. *mSphere*. 2020;5:e00827-20. d
442 oi: 10.1128/mSphere.00827-20.

443 29. Li H, et al. High Anal Swab Viral Load Predisposes Adverse Clinical Outcomes in
444 Severe COVID-19 Patients. *Emerg Microbes Infect*. 2020;1-26. doi:
445 10.1080/22221751.2020.1858700.

446 30. Castagnoli R, et al. Severe Acute Respiratory Syndrome Coronavirus 2
447 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. *JAMA*
448 *Pediatr*. 2020;174:882-889. doi: 10.1001/jamapediatrics.2020.1467.

- 449 31. Liu K, et al. Clinical features of COVID-19 in elderly patients: A comparison with
450 young and middle-aged patients. *J Infect.* 2020;80:e14-e18. doi:
451 10.1016/j.jinf.2020.03.005.
- 452 32. Grasselli G, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected
453 With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA.*
454 2020;323:1574-1581. doi: 10.1001/jama.2020.5394.
- 455 33. Tan YP, et al. Epidemiologic and clinical characteristics of 10 children with
456 coronavirus disease 2019 in Changsha, China. *J Clin Virol.* 2020;127:104353. doi:
457 10.1016/j.jcv.2020.104353.
- 458 34. Mattar S, et al. Epidemiological and viral features of a cohort of SARS-Co
459 V-2 symptomatic and asymptomatic individuals in an area of the Colombian C
460 aribbean. *Ann Clin Microbiol Antimicrob.* 2020;19:58. doi: 10.1186/s12941-020-0
461 0397-5.
- 462 35. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a
463 key role for monocytes and macrophages. *Nat Rev Immunol.* 2020;20:355-362. doi:
464 10.1038/s41577-020-0331-4.

465

466

467

468 **Figure Legends**

469

470 **Figure 1.** Proportion of patients owing to intra-familial transmission among
471 asymptomatic carriers with SARS-CoV-2 infection and COVID-19 patients

472

473 **Figure 2.** The distribution of time intervals of IgM and IgG antibody seroconversion
474 among asymptomatic carriers with SARS-CoV-2 infection and COVID-19 patients
475 during follow-up time

476

477 **Figure 3.** The dynamics of IgM and IgG antibody levels in a given COVID-19 patient
478 in Putuo district of Zhoushan, Zhejiang, China, from February 9 to March 24, 2020.

479

Table 1. Baseline information of COVID-19 patients and asymptomatic SARS-CoV-2 carriers in Ningbo and Zhoushan cities of Zhejiang province, China

	Asymptomatic carriers (N=31)	Symptomatic COVID-19 patients (N=148)	Presymptomatic COVID-19 patients (N=14)	P [*]	P ^{&}	P [#]
Gender				0.453	1.000	0.750
Male	15 (48.4)	50 (33.8)	7 (50.0)			
Female	16 (51.6)	98 (66.2)	7 (50.0)			
Age, years	42.00(24.00-55.00)	53.00(38.00-62.75)	55.00(39.50-71.00)	<0.001	0.002	1.000 [§]
<30	9 (29.0)	17 (11.5)	1 (7.1)			
30-59	18 (58.1)	89 (60.1)	8 (57.1)	0.076	0.345	1.000
≥60	4 (12.9)	42 (28.4)	5 (35.7)			
Underlying diseases				1.000	1.000	1.000
No	24 (77.4)	104 (71.7)	9 (64.3)			
Yes	7 (22.6)	41 (28.3)	5 (35.7)			
WBC, 10 ⁹ /L	5.83(5.00-7.11)	4.63(3.80-5.69)	5.83(4.73-6.75)	<0.001	1.000	0.075 [§]
Lymphocyte, 10 ⁹ /L	1.53(1.32-2.11)	1.22(0.86-1.60)	1.26(0.89-1.86)	0.003	0.420	1.000 [§]
CRP, mg/L	1.00(0.60-2.99)	6.90(2.04-18.20)	3.07(0.97-14.45)	<0.001	0.317	0.885 [§]
Viral shedding, day	24.00(21.00-30.80)	46.50(35.00-58.00)	48.00(23.75-51.25)	<0.001	0.002	1.000 [§]
qRT-PCR-CT values	31.40(27.50-34.50)	29.00(24.25-32.00)	33.50(28.25-36.25)	0.004	0.410	0.003 [§]
IgM				1.000	1.000	1.000

Negative	12 (38.7)	43 (31.9)	5 (50.0)			
Positive	19 (61.3)	91 (67.4)	5 (50.0)			
Weak Positive	0 (0.0)	1 (0.7)	0 (0.0)			
IgG				0.112	1.000	0.504
Negative	2 (6.5)	10 (7.4)	1 (10.0)			
Positive	25 (80.6)	122 (90.4)	8 (80.0)			
Weak Positive	4 (12.9)	3 (2.2)	1 (10.0)			

Abbreviations: WBC, white blood cell; CRP, C-reactive protein; CT, cycling threshold; IQR, interquartile range.

P^{*}, Asymptomatic carrier vs. Symptomatic COVID-19 patients.

P[&], Asymptomatic carrier vs. Presymptomatic COVID-19 patients.

P[#], Symptomatic COVID-19 patients vs. Presymptomatic COVID-19 patients.

§Continuous variables are expressed as median (IQR). P value was calculated using Kruskal Wallis test.

Categorical variables are expressed as n (%). P values were calculated using χ^2 test and Fisher's exact test.

Table 2. Seroconversion of IgG and/or IgM antibody against SARS-CoV-2 during follow-up time

	Overall	Asymptomatic carrier (N=15)	COVID-19 patients (N=59)	<i>P</i>
<hr/>				
Seroconversion of IgM antibody				0.647
From positive to negative	28(37.8)	8(53.3)	20(33.9)	0.234
From positive to weak positive	9(12.2)	1(6.7)	8(13.6)	0.676
Consistent negative	28(37.8)	5(33.3)	23(39.0)	0.772
Consistent positive	9(12.2)	1(6.7)	8(13.6)	0.676
Time interval of IgM antibody seroconversion, days				
From positive to negative	13.00(6.00-33.75)	7.50(4.75-11.50)	25.50(6.75-56.75)	0.030
From positive to weak positive	16.00(3.00-28.00)	12.00(12.00-12.00)	19.00(3.00-30.00)	0.694
Consistent negative	11.50(7.00-25.50)	27.00(10.00-37.00)	11.00(7.00-22.50)	0.186
Consistent positive	9.00(8.00-13.00)	13.00(13.00-13.00)	8.50(7.50-14.50)	0.558
Seroconversion of IgG antibody				0.059
From positive to negative	10(13.5)	4(26.7)	6(10.2)	0.110
From positive to weak positive	13(17.6)	4(26.7)	9(15.3)	0.446
Consistent negative	7(9.5)	2(13.3)	5(8.5)	0.624
Consistent positive	44(59.5)	5(33.3)	39(66.1)	0.037
Time interval of IgG antibody seroconversion, days				
From positive to negative	24.00(10.00-48.00)	24.00(9.25-58.75)	27.50(10.00-48.00)	1.000
From positive to weak positive	7.00(4.00-22.00)	5.50(4.25-7.75)	11.00(4.00-30.00)	0.279
Consistent negative	10.00(7.50-18.50)	9.00(8.50-9.50)	12.00(7.00-25.00)	0.699

Consistent positive	13.50(6.75-24.00)	13.00(12.00-14.00)	14.00(6.00-25.00)	0.970
---------------------	-------------------	--------------------	-------------------	-------

Data are median (IQR), n (%), P values compare using χ^2 test, Fisher's exact test, or Kruskal Wallis test. IQR, interquartile range.